β-alanine derivatives and the use thereof
A compound of the general formula (I) (wherein the symbols are as defined in the description), or a prodrug or a salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, lower urinary tract symptom (for example, occlusion disease of lower urinary tract), inflammatory disease of lower urinary tract, polyuria), carcinoma association disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leucemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation/immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease by secretion fault (Sjogren syndrome) or brain association disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy).
1. A β-alanine derivative represented by formula (I):
wherein A represents (1) C1˜6 alkylene, (2) C2˜6 alkenylene, or (3) C2˜6 alkynylene wherein A may be substituted by 1-3 of C1˜4 alkyl;
represents (1) C3˜15 carbocyclic ring, or (2) 3-15 membered heterocyclic ring containing 1-4 of nitrogen atom(s), 1-2 of oxygen atom(s) and/or 1-2 of sulfur atom(s);
R 1 represents (1) C1˜4 alkyl, (2) a halogen atom, (3) cyano, (4) trihalomethyl, (5) —OR 6 , (6) —SR 7 , (7) —NR 8 R 9 , (8) nitro, (9) —COOR 10 , (10) —CONR 11 R 12 , (11) —NR 13 COR 14 , (12) —SO 2 NR 15 R 16 , (13) —NR 17 SO 2 R 18 , (14) —S(O)R 19 or (15) —SO 2 R 20 ;
R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 20 each independently represents (1) a hydrogen atom or (2) C1˜4 alkyl;
R 2 and R 3 each independently represents (1) C1˜4 alkyl, (2) C1˜4 alkoxy or (3) a halogen atom;
R 4 and R 5 each independently represents (1) a hydrogen atom, (2) C1˜4 alkyl, (3) C2˜4 alkenyl, (4) C2˜4 alkynyl, (5) C1˜4 alkyl substituted by —OR 21 , (6) C1˜4 alkyl substituted by —NR 22 R 23 or (7)
R 4 and R 5 taken together with nitrogen atom to which they are attached represents 3-15 membered mono-, bi- or tricyclic heterocyclic ring wherein the heterocyclic ring contains at least one nitrogen atom and may be substituted by C1˜4 alkyl substituted by —OR 25 ;
R 21 , R 22 , R 23 and R 25 each independently represents (1) a hydrogen atom, (2) C1˜4 alkyl (3) C2˜6 acyl or (4) trihaloacetyl;
E represents (1) single bond, (2) C1˜6 alkylene, (3) C2˜6 alkenylene or (4) C2˜6 alkynylene wherein E may be substituted by C1˜4 alkyl substituted by 1-3 of group(s) selected from (1) C1˜4 alkyl and (2) —OR 26 ;
R 26 represents (1) a hydrogen atom, (2) C1˜4 alkyl, (3) C2˜6 acyl or (4) trihaloacetyl;
represents (1) C3˜15 carbocyclic ring or (2) 3-15 membered heterocyclic ring containing 1-4 of nitrogen atom(s), 1-2 of oxygen atom(s) and/or 1-2 of sulfur atom(s);
R 24 represents (1) C1˜4 alkyl, (2) a halogen atom, (3) cyano, (4) trihalomethyl, (5) —OR 27 , (6) —SR 28 , (7) —NR 29 R 30 , (8) nitro, (9) —COOR 31 , (10) —CONR 32 R 33 , (11) —NR 34 COR 35 , (12) —SO 2 NR 36 R 37 , (13) —R 38 SO 2 R 39 , (14) —S(O)R 40 or (15) —SO 2 R 41 ;
R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 and R 41 each independently represents (1) a hydrogen atom or (2) C1˜4 alkyl;
i represents 0 or an integer of 1˜5;
m represents 0 or an integer of 1˜4;
n represents 0 or an integer of 1˜4;
p represents 0 or an integer of 1˜5;
wherein when i is 2 or more, plural R 1 are the same or different; when m is 2 or more, plural R 2 are the same or different; when n is 2 or more, plural R 3 are the same or different; when p is 2 or more, plural R 24 are the same or different,
or a prodrug thereof or a salt thereof;
wherein said prodrug is selected from the group consisting of the compound of formulas (IA), (IB) and (IC):
wherein R 42 represents (1) C1˜8 alkyl or (2) C1˜8 alkyl substituted by 1-2 of hydroxyl or amino;
wherein R 43 and R 44 each independently represents (1) a hydrogen atom, (2) C1˜8 alkyl or (3) C1˜8 alkyl substituted by 1-2 of hydroxyl or amino;
2. The prodrug according to claim 1 , which is represented by the formula (IA).
3. The prodrug according to claim 1 , which is represented by the formula (IB).
4. The prodrug according to claim 1 , which is represented by the formula (IC).
5. A pharmaceutical composition comprising the compounds according to claim 1 , or the prodrug thereof or the salt thereof and a pharmaceutically acceptable carrier.